Most Read Articles
Jairia Dela Cruz, 5 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
6 days ago
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.

Mirabegron plus solifenacin shows promise in overactive bladder treatment

Jairia Dela Cruz
13 Sep 2018

A 12-month treatment course with the combination of mirabegron plus solifenacin is safe and effective in patients with overactive bladder (OAB), reducing the number of incontinence episodes and micturition without unexpected toxicities, according to the results of the phase III SYNERGY II study.

“These favourable long-term data showcase the potential of [the said] novel combination treatment option for patients with OAB,” who require long-term treatment to achieve adequate symptom control, the investigators said.

The analysis included 1,794 patients (median age 60 years; 80 percent female) with “wet” OAB symptoms (urinary frequency and urgency with incontinence) for ≥3 months. Following a 2-week placebo run-in, these patients were randomized to 12-month treatment with solifenacin succinate 5 mg plus mirabegron 50 mg (combination; n=1,193), solifenacin 5 mg alone (n=299), or mirabegron 50 mg alone (n=302).

The combination therapy yielded superior reductions in the number of incontinence episodes compared with mirabegron monotherapy (adjusted mean difference [AMD], −0.5; 95 percent CI, −0.7 to −0.2; p<0.001) and solifenacin monotherapy (AMD, −0.1; −0.4 to 0.1; p=0.002). [Eur Urol 2018;doi:10.1016/j.eururo.2018.05.005]

Likewise, improvements in micturition were better with the combination therapy vs mirabegron alone (AMD, −0.5; −0.8 to −0.2; p<0.001) and solifenacin alone (AMD, −0.4; −0.7 to −0.1; p=0.004).

A total of 856 patients (47 percent) had ≥1 treatment-emergent adverse events (TEAEs), the primary safety outcome. TEAEs occurred with slightly greater frequency in the combination group vs the solifenacin and mirabegron monotherapy groups (49 percent vs 41 percent vs 44 percent, respectively), with dry mouth being the most common event.

Serious TEAEs were reported in 67 patients (3.7 percent), with one case of atrial fibrillation in the mirabegron group considered to be potentially related to treatment.

The present data confirm and extend the results of the 12-week phase III SYNERGY study, which has shown clinically relevant improvements in incontinence episodes and micturition after short-term treatment with solifenacin 5 mg in combination with mirabegron 25 or 50 mg as compared with the individual monotherapies in the general OAB population with urinary incontinence. [BJU Int 2017;120:562-575]

“Mirabegron and solifenacin have different mechanisms of action, and coadministration appears to have no noticeable effect on their pharmacokinetics,” the investigators noted.

Indeed, findings from the present and previous studies have demonstrated that combination treatment for 12 weeks up to 1 year improves OAB outcomes without a substantial impact on the safety profile when compared with monotherapies. [J Urol 2016;196:809-818; Eur Urol 2016;70:136-145]

The study has several limitations, including the fact that most of the patients enrolled had completed the previous studies evaluating the efficacy and safety of short-term solifenacin–mirabegron treatment for OAB.

As a result, the population may have been skewed towards those who had experienced a favourable response and/or positive safety outcome following combination treatment or monotherapy, the investigators pointed out.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 5 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
6 days ago
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.